- Home
- EYPT vs MYGN Comparison
EYPT vs MYGN Comparison
Compare EYPT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- MYGN
- Stock Information
- Founded
- EYPT 1987
- MYGN 1991
- Country
- EYPT United States
- MYGN United States
- Employees
- EYPT N/A
- MYGN N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EYPT Industrials
- MYGN Health Care
- Exchange
- EYPT Nasdaq
- MYGN Nasdaq
- Market Cap
- EYPT 741.0M
- MYGN 642.0M
- IPO Year
- EYPT 2005
- MYGN 1995
- Fundamental
- Price
- EYPT $13.76
- MYGN $7.68
- Analyst Decision
- EYPT Strong Buy
- MYGN Hold
- Analyst Count
- EYPT 6
- MYGN 13
- Target Price
- EYPT $25.83
- MYGN $13.50
- AVG Volume (30 Days)
- EYPT 823.7K
- MYGN 1.4M
- Earning Date
- EYPT 11-06-2025
- MYGN 11-06-2025
- Dividend Yield
- EYPT N/A
- MYGN N/A
- EPS Growth
- EYPT N/A
- MYGN N/A
- EPS
- EYPT N/A
- MYGN N/A
- Revenue
- EYPT $51,898,000.00
- MYGN $832,900,000.00
- Revenue This Year
- EYPT N/A
- MYGN $0.17
- Revenue Next Year
- EYPT N/A
- MYGN $6.19
- P/E Ratio
- EYPT N/A
- MYGN N/A
- Revenue Growth
- EYPT 2.99
- MYGN 3.83
- 52 Week Low
- EYPT $3.91
- MYGN $3.76
- 52 Week High
- EYPT $14.42
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- EYPT 66.97
- MYGN 69.11
- Support Level
- EYPT $12.88
- MYGN $7.13
- Resistance Level
- EYPT $14.15
- MYGN $7.80
- Average True Range (ATR)
- EYPT 0.76
- MYGN 0.44
- MACD
- EYPT 0.02
- MYGN 0.05
- Stochastic Oscillator
- EYPT 79.11
- MYGN 92.45
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.